{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:12Z","timestamp":1788243372395,"version":"build-2803163510"},"reference-count":16,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: In multiple myeloma, extramedullary involvement confers poor prognosis. Extramedullary involvement in multiple myeloma may manifest at the time of diagnosis or during a relapse, and it represents a severe condition. Patients with bone involvement are referred to as EM-B, while those with soft tissue involvement are referred to as EM-S. Although various studies have been conducted, the number of studies that categorize extramedullary involvement and examine the effects of flow cytometry, treatment, and genetic findings on prognosis is quite limited. We aimed to contribute to the literature by addressing this gap. Methods: In our study, we retrospectively examined the data of 281 patients followed at our center between 2011 and 2023. Clinical\/laboratory data and flow cytometry profiles were collected. Survival was analyzed using Kaplan\u2013Meier and Cox models; logistic regression was used for categorical variables. Hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated; p-values were reported to three decimals. Results: Extramedullary involvement was absent in 134 (47.7%) patients, while involvement was detected in 147 (52.3%) patients. The median age of the patients was 60 years, and the median follow-up period was 35.4 months. No association was found between CD56 expression on plasma cells, higher Revised Multiple Myeloma International Staging System (R-ISS) score, and extramedullary involvement. Overall survival (OS) was found to be significantly lower in patients with extramedullary involvement. Conclusions: The findings of our study are consistent with many studies in the literature, supporting the finding that survival rates are lower in myeloma patients with extramedullary involvement. Further studies are needed to elucidate the pathogenesis in patients with extramedullary involvement in multiple myeloma and to provide a basis for targeted therapies. Studies involving immunotherapy and cellular therapies may offer a new avenue for these patients.<\/jats:p>","DOI":"10.3390\/jcm15176765","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:45:13Z","timestamp":1788241513000},"page":"6765","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Affecting Prognosis in Patients with Extramedullary Myeloma: A Single-Center Experience"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-3121","authenticated-orcid":false,"given":"Ersin","family":"Bozan","sequence":"first","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4081-1070","authenticated-orcid":false,"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"G\u00f6kcen","family":"Bozan","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Mahmut Esad","family":"Durmu\u015f","sequence":"additional","affiliation":[{"name":"Internal Medicine Clinic, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-8984","authenticated-orcid":false,"given":"Burcu","family":"Aslan Cand\u0131r","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"U\u011fur","family":"Hatipo\u011flu","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-8163","authenticated-orcid":false,"given":"Bar\u0131\u015f","family":"Boral","sequence":"additional","affiliation":[{"name":"Immunology Department, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Dicle","family":"\u0130skender","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Bahar","family":"Uncu Ulu","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Tu\u011f\u00e7e Nur","family":"Yi\u011feno\u011flu","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Beksac","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hatipo\u011flu, U., Seyhan, M., Ulas, T., Dal, M.S., and Altunta\u015f, F. (2025). Solitary Plasmacytomas: Current Status in 2025. Hematol. Rep., 17.","DOI":"10.3390\/hematolrep17040032"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/1754-9485.12975","article-title":"Imaging features of extramedullary plasmacytoma","volume":"64","author":"Ryu","year":"2020","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4274\/tjh.galenos.2019.2019.0061","article-title":"Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis","volume":"37","author":"Aksu","year":"2020","journal-title":"Turk. J. Haematol."},{"key":"ref_6","first-page":"777","article-title":"Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors","volume":"31","author":"Wang","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_7","first-page":"14","article-title":"Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases","volume":"53","author":"Chen","year":"2023","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3324\/haematol.2020.278272","article-title":"A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome","volume":"106","author":"Beksac","year":"2021","journal-title":"Haematologica"},{"key":"ref_13","first-page":"26","article-title":"The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients","volume":"34","author":"Ceran","year":"2017","journal-title":"Turk. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2141.2002.03513.x","article-title":"Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma","volume":"117","author":"Sahara","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ho, M., Paruzzo, L., Minehart, J., Nabar, N., Noll, J.H., Luo, T., Garfall, A., and Zanwar, S. (2025). Extramedullary Multiple Myeloma: Challenges and Opportunities. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32030182"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6765\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:58:56Z","timestamp":1788242336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":16,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176765"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176765","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}